Atopic Dermatitis conjures up thoughts of stressed animals, unhappy owners and frustrated veterinarians. Unfortunately, Atopy, is fairly common as the second most prevalent allergic skin disease in dogs. Around 16% of all dogs are affected by Atopy and 10% of cats. According to VPI (Vet Pet Insurance) in 2012, Atopy became the number one ailment to bring dog owners to veterinary clinics and number one reimbursed claim in terms of the expense of current drugs and the chronic treatment of the disease. Though Atopy is common, traditional medical management is lacking effectiveness.
A study is underway at Kansas State University that expects to offer veterinarians this tool for an effective Atopy treatment. Case after case has been demonstrated with substantial results using stem cell therapy. Selecting a strong partner in research is important. Dr. Mark Weiss at Kansas State University has spent the majority of his career learning, reading and better understanding Mesenchymal Stem Cells (MSCs) from various tissue sources for potential therapeutic application. His expertise in the field of regenerative medicine provided synergies for a partnership with MediVet Biologics.
Kansas State University is an ideal partner to perform a pilot study to estimate the clinical effect size and safety of SVF in dogs with Atopy. This is an institutional animal care and use committee (IACUC ) approved, multi-center, randomized, double blind, placebo controlled clinical pilot study with a 2: 1 allocation ratio ( 2 Dogs will receive SVF to 1 dog that receives the control ).